Other studies such as the GALATIC-HF trial evaluated Omecamtiv Mecarbil in patients with HFrEF with current or recent (<1 year) admission for HF, with a percentage of NYHA functional class III–IV and NT-proBNP levels similar to VICTORIA-HF. Here, NPPB is linked to hydrops fetalis.